{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "c6ab2911",
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "import re\n",
    "import pandas as pd\n",
    "from datetime import datetime\n",
    "# pip install reductoai\n",
    "from pathlib import Path\n",
    "from reducto import AsyncReducto\n",
    "import asyncio\n",
    "import os \n",
    "from dotenv import load_dotenv\n",
    "\n",
    "# Load variables from .env into environment\n",
    "load_dotenv()\n",
    "\n",
    "OPENAI_API_KEY = os.getenv(\"OPENAI_API_KEY\")\n",
    "REDUCTO_API_KEY = os.getenv(\"REDUCTO_API_KEY\")\n",
    "import time\n",
    "import matplotlib.pyplot as plt\n",
    "%matplotlib inline\n",
    "\n",
    "\n",
    "client = AsyncReducto()\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 183,
   "id": "146a5759",
   "metadata": {},
   "outputs": [],
   "source": [
    "async def run_reducto(file):\n",
    "    # Replace with your file path\n",
    "    start = time.perf_counter()\n",
    "    print(f\"[{datetime.now():%H:%M:%S}] START {file}\")\n",
    "    upload = await client.upload(file=Path(file))\n",
    "    print(f\"[{datetime.now():%H:%M:%S}] UPLOADED {file}\")\n",
    "\n",
    "    result = await client.pipeline.run(\n",
    "        input=upload,\n",
    "        pipeline_id=\"k97e5ryq6b73xmqjbjxaedy8rn7vw541\"\n",
    "    )\n",
    "    elapsed = time.perf_counter() - start\n",
    "\n",
    "    print(f\"[{datetime.now():%H:%M:%S}] DONE {file} in {elapsed:.1f}s\")\n",
    "\n",
    "    final_result = result.result.extract.result \n",
    "    \n",
    "    # Extract just the filename from the path\n",
    "    filename = Path(file).stem  # Gets filename without extension\n",
    "    # Ensure output directory exists\n",
    "    os.makedirs(\"trial_outputs\", exist_ok=True)\n",
    "    \n",
    "    #write final result to json file \n",
    "    with open(f\"trial_outputs/trial_{filename}.json\", \"w\") as f:\n",
    "        json.dump(final_result, f)\n",
    "    return final_result"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 184,
   "id": "6d0e2379",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Found 2 PDF files:\n",
      "  - trials/pt2/125_2015_Article_3795.pdf\n",
      "  - trials/pt2/zdc1255.pdf\n"
     ]
    }
   ],
   "source": [
    "# Automatically collect all PDF files from trials folder\n",
    "trials_dir = Path(\"trials/pt2/\")\n",
    "trial_paths = [str(pdf_file) for pdf_file in trials_dir.glob(\"*.pdf\")]\n",
    "print(f\"Found {len(trial_paths)} PDF files:\")\n",
    "for path in trial_paths:\n",
    "    print(f\"  - {path}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 185,
   "id": "38aadc4a",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "async def run_reducto_batch(trials): \n",
    "    tasks = [run_reducto(t) for t in trials]\n",
    "\n",
    "    return await asyncio.gather(*tasks)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 186,
   "id": "01b4d922",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[13:14:42] START trials/pt2/125_2015_Article_3795.pdf\n",
      "[13:14:42] START trials/pt2/zdc1255.pdf\n",
      "[13:14:43] UPLOADED trials/pt2/125_2015_Article_3795.pdf\n",
      "[13:14:43] UPLOADED trials/pt2/zdc1255.pdf\n",
      "[13:16:31] DONE trials/pt2/zdc1255.pdf in 109.4s\n",
      "[13:19:18] DONE trials/pt2/125_2015_Article_3795.pdf in 276.2s\n"
     ]
    }
   ],
   "source": [
    "final_result = await run_reducto_batch(trial_paths)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "2d02324b",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "\n",
    "def load_reducto_results(input):\n",
    " \n",
    "    trials = []\n",
    "    baseline_rows = []\n",
    "    ae_rows = []\n",
    "\n",
    "    for i, trial_obj in enumerate(input):\n",
    "        trial_obj = trial_obj[0]\n",
    "        md = trial_obj[\"trial_metadata\"]\n",
    "\n",
    "        # ---- trial_id / NCT handling ----\n",
    "        nct = md[\"NCT Number\"]\n",
    "        \n",
    "        trial_id = nct\n",
    "        if trial_id == \"N/A\": \n",
    "            trial_id = f\"{md['drug_name']}_{i+1}\"\n",
    "        print(trial_id)\n",
    "        # ---- trials table row ----\n",
    "        trial_row = {\n",
    "            \"trial_id\": trial_id,\n",
    "            \"citation\": md[\"citation\"],\n",
    "            \"drug_name\": md[\"drug_name\"],\n",
    "            \"phase\": md[\"phase\"],\n",
    "            \"indication\": md[\"indication\"],\n",
    "            \"trial_duration\": md[\"trial_duration\"],\n",
    "            \"trial_duration_weeks\": md[\"numeric_trial_duration\"],\n",
    "            \"safety_population_definition\": md[\"safety_population_definition\"],\n",
    "            \"nct_number\": nct or None,\n",
    "            \"sponsor\": md[\"Sponsor\"],\n",
    "        }\n",
    "\n",
    "        # numeric duration in weeks (if it exists)\n",
    "        dur = md[\"trial_duration\"] or \"\"\n",
    "        m = re.search(r\"(\\d+)\\s*week\", dur.lower())\n",
    "      #  trial_row[\"trial_duration_weeks\"] = int(m.group(1)) if m else None\n",
    "\n",
    "        trials.append(trial_row)\n",
    "\n",
    "        # ---- baseline table rows ----\n",
    "        for row in trial_obj[\"baseline_table\"]:\n",
    "            arm = row[\"arm_result\"] or {}\n",
    "            baseline_rows.append({\n",
    "                \"trial_id\": trial_id,\n",
    "                \"variable_label\": row[\"variable_label\"],\n",
    "                \"variable_label_raw\": row[\"variable_label_raw\"],\n",
    "                \"categorical_label\": row[\"categorical_label\"],\n",
    "                \"variable_type\": row[\"variable_type\"],\n",
    "                \"units\": row[\"units\"],\n",
    "\n",
    "                \"arm_label\": arm[\"arm_label\"],\n",
    "                \"arm_role\": arm[\"arm_role\"],\n",
    "                \"arm_total_n\": arm[\"total_n\"],\n",
    "\n",
    "                \"n\": arm[\"n\"],\n",
    "                \"percent\": arm[\"percent\"],\n",
    "                \"mean\": arm[\"mean\"],\n",
    "                \"sd\": arm[\"sd\"],\n",
    "                \"raw_value\": arm[\"raw_value\"],\n",
    "            })\n",
    "\n",
    "        # ---- AE table rows ----\n",
    "        for row in trial_obj[\"ae_events\"]:\n",
    "            arm = row[\"arm_result\"] or {}\n",
    "            ae_rows.append({\n",
    "                \"trial_id\": trial_id,\n",
    "                \"AE_label_raw\": row[\"AE_label_raw\"],\n",
    "                \"event_category\": row[\"event_category\"],\n",
    "                \"is_any_ae\": row[\"is_any_ae\"],\n",
    "                \"is_serious_ae\": row[\"is_serious_ae\"],\n",
    "                \"is_fatal\": row[\"is_fatal\"],\n",
    "                \"is_ae_leading_to_discontinuation\": row[\"is_ae_leading_to_discontinuation\"],\n",
    "                \"is_aesi\": row[\"is_aesi\"],\n",
    "\n",
    "                \"arm_label\": arm[\"arm_label\"],\n",
    "                \"arm_role\": arm[\"arm_role\"],\n",
    "                \"arm_total_n\": arm[\"total_n\"],\n",
    "                \"n_with_event\": arm[\"n_with_event\"],\n",
    "                \"percent_with_event\": arm[\"percent_with_event\"],\n",
    "            })\n",
    "\n",
    "    df_trials = pd.DataFrame(trials)\n",
    "    df_baseline = pd.DataFrame(baseline_rows)\n",
    "    df_ae = pd.DataFrame(ae_rows)\n",
    "\n",
    "    return df_trials, df_baseline, df_ae\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "id": "ea63ccdf",
   "metadata": {},
   "outputs": [],
   "source": [
    "## load in json files from trial outputs and append to them a list to run load_reducto_results on them \n",
    "trials_json_files = [f for f in os.listdir(\"trial_outputs\") if f.endswith(\".json\")]\n",
    "final_result = []\n",
    "for file in trials_json_files:\n",
    "    with open(f\"trial_outputs/{file}\", \"r\") as f:\n",
    "        trial_obj = json.load(f)\n",
    "    final_result.append(trial_obj)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "id": "551858b5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "NCT01272219\n",
      "NCT03495102\n",
      "NCT03548935\n",
      "NCT00849017\n",
      "NCT05567796\n",
      "NCT04707469\n",
      "Exenatide (Exendin-4)_7\n",
      "NCT04944992\n",
      "NCT00688701\n",
      "NCT00308139\n",
      "NCT05669599\n",
      "NCT00381342\n",
      "NCT02465515\n",
      "NCT04184622\n",
      "Exenatide (Byetta)_15\n",
      "NCT00707031\n",
      "NCT05035095\n",
      "NCT04881760\n"
     ]
    }
   ],
   "source": [
    "df_trials, df_baseline, df_ae = load_reducto_results(\n",
    "    final_result\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "id": "3e6d0866",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "(172,\n",
       " 908                         AE leading to discontinuation\n",
       " 960                                  Abdominal distension\n",
       " 14                                         Abdominal pain\n",
       " 323                                  Abdominal pain upper\n",
       " 880                                   Acute cholecystitis\n",
       " 682                            Acute gallbladder diseases\n",
       " 335                                   Acute kidney injury\n",
       " 83                                     Acute pancreatitis\n",
       " 92                                     Acute renal events\n",
       " 151                                   Acute renal failure\n",
       " 235     Adverse event leading to permanent trial-produ...\n",
       " 164                   Adverse event leading to withdrawal\n",
       " 395                                        Adverse events\n",
       " 0                       Adverse events in ≥5% of patients\n",
       " 105     Adverse events leading to discontinuation of d...\n",
       " 1031    Adverse events leading to discontinuation of r...\n",
       " 772     Adverse events leading to discontinuation of t...\n",
       " 284     Adverse events leading to discontinuation of t...\n",
       " 470     Adverse events leading to discontinuation of t...\n",
       " 926     Adverse events leading to trial product discon...\n",
       " Name: AE_label_raw, dtype: object)"
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ae_labels = (\n",
    "    df_ae[\"AE_label_raw\"]\n",
    "    .dropna()\n",
    "    .drop_duplicates()\n",
    "    .sort_values()\n",
    ")\n",
    "len(ae_labels), ae_labels[:20]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "83a59c0b",
   "metadata": {},
   "outputs": [],
   "source": [
    "ae_labels.to_csv(\"ae_labels_raw.csv\", index=False)\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7d4ce0f8",
   "metadata": {},
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "c086587a",
   "metadata": {},
   "outputs": [],
   "source": [
    "from openai import OpenAI\n",
    "import os\n",
    "client = OpenAI()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "ca1d76f5",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "def build_prompt_for_labels(labels):\n",
    "    instructions = \"\"\"\n",
    "You are harmonizing adverse event labels from clinical trial safety tables.\n",
    "\n",
    "Goal:\n",
    "- Assign a canonical name for each label (ae_canonical) that merges variants of the same concept.\n",
    "- Also assign a slightly broader \"family\" grouping (ae_family) that merges clearly related variants that may be slighlty clinically that someone would reasonably collapse for analysis when evaluating the AE profile of a drug.\n",
    "- Do NOT merge clinically distinct events that are routinely reported separately (for example,\n",
    "  \"Nausea\" vs \"Vomiting\" vs \"Diarrhea\" should each remain their own family) Remember these should be actually clinically distinct rathan a severe vs serious event. Imagine you are using these labels\n",
    "  as a doctor to make treatment decisions. \n",
    "\n",
    "Definitions:\n",
    "- ae_canonical:\n",
    "  - A preferred term for the adverse event concept.\n",
    "  - Examples:\n",
    "    - \"Cholecystitis acute\" -> ae_canonical = \"Acute cholecystitis\"\n",
    "    - \"Chronic cholecystitis\" -> ae_canonical = \"Chronic cholecystitis\"\n",
    "    - \"Cholelithiasis\" -> ae_canonical = \"Cholelithiasis\"\n",
    "    - \"Nausea\" -> ae_canonical = \"Nausea\"\n",
    "    - \"Renal event\" -> ae_canonical = \"Renal impairment\"\n",
    "    - \"Renal disorder\" -> ae_canonical = \"Renal impairment\"\n",
    "    - \"Hyperglycemic episode\" -> ae_canonical = \"Hyperglycemia\"\n",
    "    - \"Hyperglycemia > 54 mg/dL\" -> ae_canonical = \"Hyperglycemia\"\n",
    "\n",
    "- ae_family:\n",
    "  - A slightly broader grouping that clusters very closely related variants and subtypes.\n",
    "  - Use the same ae_family for labels that are essentially the same clinical topic and would often be\n",
    "    grouped together in a safety analysis (e.g., different subtypes of cholecystitis, or different\n",
    "    phrasings of the same AE).\n",
    "  - Examples:\n",
    "    - If clinically reasonable, \"Cholelithiasis\" and \"Cholecystitis\" may share ae_family = \"Gallbladder disease\".\n",
    "    - \"Nausea\" and \"Vomiting\" should NOT be merged into the same ae_family; each stays in its own family.\n",
    "  - If no broader grouping is natural, set ae_family equal to ae_canonical.\n",
    "\n",
    "- Summary rows:\n",
    "  - Some labels are global summaries such as \"Any adverse event\", \"Serious adverse events\",\n",
    "    \"Adverse events leading to discontinuation\".\n",
    "  - These should be marked as is_summary = true and given an appropriate summary_type.\n",
    "  - For summary rows, ae_canonical and ae_family may reflect the summary (e.g. \"Any adverse event\",\n",
    "    \"Serious adverse events\") rather than a specific PT.\n",
    "\n",
    "For EACH label I give you, output a JSON object with:\n",
    "- \"label_raw\": the original label string.\n",
    "- \"ae_canonical\": a short, specific canonical name as defined above.\n",
    "- \"ae_family\": the broader family name as defined above. If no broader grouping is natural,\n",
    "  set ae_family equal to ae_canonical.\n",
    "- \"is_summary\": true if this label describes a global summary row\n",
    "  (e.g. \"Any adverse event\", \"Serious adverse events\", \"Adverse events leading to discontinuation\"),\n",
    "  otherwise false.\n",
    "- \"summary_type\": if is_summary is true, one of:\n",
    "  - \"any_ae\"\n",
    "  - \"serious_ae\"\n",
    "  - \"fatal_ae\"\n",
    "  - \"ae_leading_to_discontinuation\"\n",
    "  - \"other_summary\"\n",
    "  Otherwise null.\n",
    "- \"notes\": (optional) short explanation of your reasoning if needed.\n",
    "- \"confidence\": \"high\", \"medium\", or \"low\".\n",
    "\n",
    "Return ONLY a JSON list (array) of these objects, with one object per label, and no extra commentary.\n",
    "\n",
    "Here are the labels:\n",
    "\"\"\"\n",
    "    body = \"\\n\".join(f\"- {lab}\" for lab in labels)\n",
    "    return instructions + \"\\n\" + body\n",
    " "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "6342da60",
   "metadata": {},
   "outputs": [],
   "source": [
    "mapping = []\n",
    "canonical_set = []\n",
    "prompt = build_prompt_for_labels( ae_labels)\n",
    "ae_response = client.chat.completions.create(\n",
    "    model=\"gpt-5\",\n",
    "    messages=[{\"role\": \"user\", \"content\": prompt}],\n",
    "    response_format={\"type\": \"json_object\"},\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 195,
   "id": "8bee6bde",
   "metadata": {},
   "outputs": [],
   "source": [
    "ae_result = json.loads(ae_response.choices[0].message.content)\n",
    "ae_mapping = pd.DataFrame(ae_result['result'])\n",
    "ae_mapping.head()\n",
    "new_df_ae = df_ae.merge(\n",
    "    ae_mapping[[\"label_raw\", \"ae_canonical\", \"ae_family\", \"is_summary\", \"summary_type\"]],\n",
    "    left_on=\"AE_label_raw\",\n",
    "    right_on=\"label_raw\",\n",
    "    how=\"left\",\n",
    ")\n",
    "new_df_ae = new_df_ae.merge(\n",
    "    df_trials[[\"trial_id\", \"drug_name\"]],\n",
    "    on=\"trial_id\",\n",
    "    how=\"left\",\n",
    ")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 196,
   "id": "dd5e5255",
   "metadata": {},
   "outputs": [],
   "source": [
    "# nausea = new_df_ae[new_df_ae[\"ae_canonical\"] == \"Nausea\"].copy()\n",
    "\n",
    "# # use drug name instead of trial_id in the label\n",
    "# nausea[\"arm_display\"] = (\n",
    "#     nausea[\"drug_name\"].fillna(nausea[\"trial_id\"])  # fallback if drug_name missing\n",
    "#     + \" | \" +\n",
    "#     nausea[\"arm_label\"]\n",
    "# )\n",
    "\n",
    "# # sort by % nausea\n",
    "# nausea = nausea.sort_values(\"percent_with_event\", ascending=True)\n",
    "\n",
    "# plt.figure(figsize=(10, 6))\n",
    "# plt.barh(nausea[\"arm_display\"], nausea[\"percent_with_event\"])\n",
    "# plt.xlabel(\"Nausea (% participants with ≥1 event)\")\n",
    "# plt.ylabel(\"Drug | Arm\")\n",
    "# plt.title(\"Nausea incidence by arm\")\n",
    "# plt.tight_layout()\n",
    "# plt.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 197,
   "id": "b6fd82c2",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_arms = (\n",
    "    new_df_ae[[\"trial_id\", \"arm_label\", \"arm_role\", \"drug_name\"]]\n",
    "    .drop_duplicates()\n",
    "    .reset_index(drop=True)\n",
    ")\n",
    "df_arms = df_arms.merge(\n",
    "    df_trials[[\"trial_id\", \"phase\", \"indication\"]],\n",
    "    on=\"trial_id\",\n",
    "    how=\"left\",\n",
    ")\n",
    "\n",
    "def build_arm_prompt(arms_batch):\n",
    "    \"\"\"\n",
    "    arms_batch: list of dicts with keys: trial_id, arm_label, drug_name, phase, indication, arm_role\n",
    "    \"\"\"\n",
    "    instructions = \"\"\"\n",
    "You are helping analyze clinical trial arms for GLP-1 and related drugs.\n",
    "\n",
    "For each trial arm, decide if it represents a clinically relevant dose that would\n",
    "likely be used in real-world practice (approved dose or something very close to it),\n",
    "as opposed to:\n",
    "- clear sub-therapeutic exploratory doses\n",
    "- run-in/titration-only schedules\n",
    "- placebo or non-active comparator arms.\n",
    "\n",
    "Guidelines:\n",
    "- Placebo arms are NEVER clinically relevant.\n",
    "- Arms with obviously tiny doses (e.g. early phase 0.25 mg where the drug is normally used at 1–2+ mg)\n",
    "  are usually NOT clinically relevant unless that is an approved maintenance dose.\n",
    "- If multiple doses are approved (e.g. 1.0 mg and 2.4 mg), they can all be clinically relevant.\n",
    "- If you are unsure, be conservative and set is_clinical_dose = true.\n",
    "- If it is not approved yet, typically select the dose with the best balance of efficacy and safety that would be a fair comparison to other approved drugs\n",
    "\n",
    "For EACH arm I give you, output a JSON object with:\n",
    "- \"trial_id\"\n",
    "- \"arm_label\"\n",
    "- \"drug_name\"\n",
    "- \"dose_mg\": numeric dose if you can parse it from the arm_label (e.g. 1.0, 2.4, 50).\n",
    "  If unclear, use null.\n",
    "- \"route\": short route if obvious from context (e.g. \"SC\", \"oral\", \"IV\"), else null.\n",
    "- \"frequency\": short dosing frequency (e.g. \"QD\", \"BID\", \"QW\", \"Q2W\", \"Q4W\"), else null.\n",
    "- \"is_placebo\": true if this is clearly a placebo arm.\n",
    "- \"is_clinical_dose\": true if this arm is a clinically relevant, real-world dose as defined above.\n",
    "- \"include_in_plot\": true if you think this arm should be included when plotting\n",
    "  dose vs adverse events; typically true for active clinically relevant doses, false for placebo and\n",
    "  non-relevant exploratory doses.\n",
    "- \"notes\": optional, brief explanation if needed.\n",
    "- \"confidence\": \"high\", \"medium\", or \"low\".\n",
    "\n",
    "Return ONLY a JSON list (array) of these objects, no extra commentary.\n",
    "\n",
    "Here are the trial arms:\n",
    "\"\"\"\n",
    "    lines = []\n",
    "    for arm in arms_batch:\n",
    "        # provide a little structured context\n",
    "        context = {\n",
    "            \"trial_id\": arm[\"trial_id\"],\n",
    "            \"drug_name\": arm[\"drug_name\"],\n",
    "            \"arm_label\": arm[\"arm_label\"],\n",
    "            \"arm_role\": arm.get(\"arm_role\"),\n",
    "            \"phase\": arm.get(\"phase\"),\n",
    "            \"indication\": arm.get(\"indication\"),\n",
    "        }\n",
    "        lines.append(json.dumps(context))\n",
    "    return instructions + \"\\n\" + \"\\n\".join(lines)\n",
    "prompt = build_arm_prompt(df_arms.to_dict(orient=\"records\"))\n",
    "arm_response = client.chat.completions.create(\n",
    "    model=\"gpt-5\",\n",
    "    messages=[{\"role\": \"user\", \"content\": prompt}],\n",
    "    response_format={\"type\": \"json_object\"},\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 198,
   "id": "cf3ced8e",
   "metadata": {},
   "outputs": [],
   "source": [
    "arm_text = arm_response.choices[0].message.content\n",
    "arm_mapping = pd.DataFrame(json.loads(arm_text)[\"results\"])\n",
    "arm_mapping.head()\n",
    "new_df_ae = new_df_ae.merge(\n",
    "    arm_mapping[[\"trial_id\", \"arm_label\", \"is_clinical_dose\", \"include_in_plot\", \"dose_mg\", \"route\", \"frequency\"]],\n",
    "    on=[\"trial_id\", \"arm_label\"],\n",
    "    how=\"left\",\n",
    ")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 199,
   "id": "b634dd64",
   "metadata": {},
   "outputs": [],
   "source": [
    "\n",
    "# # restrict to nausea + arms the model says are worth plotting\n",
    "# mask = (\n",
    "#     (new_df_ae[\"ae_canonical\"] == \"Nausea\") &\n",
    "#     (new_df_ae[\"include_in_plot\"] == True)\n",
    "# )\n",
    "\n",
    "# nausea = new_df_ae[mask].copy()\n",
    "\n",
    "# # make a nice display label: drug + dose + freq\n",
    "# def make_label(row):\n",
    "#     bits = [row[\"drug_name\"]]\n",
    "#     if pd.notna(row.get(\"dose_mg\")):\n",
    "#         bits.append(f'{row[\"dose_mg\"]} mg')\n",
    "#     if pd.notna(row.get(\"frequency\")):\n",
    "#         bits.append(row[\"frequency\"])\n",
    "#     # fallback if we didn't parse anything sensible\n",
    "#     if len(bits) == 1:\n",
    "#         bits.append(row[\"arm_label\"])\n",
    "#     return \" \".join(str(b) for b in bits if b)\n",
    "\n",
    "# nausea[\"arm_display\"] = nausea.apply(make_label, axis=1)\n",
    "\n",
    "# # sort by nausea %\n",
    "# nausea = nausea.sort_values(\"percent_with_event\", ascending=True)\n",
    "\n",
    "# plt.figure(figsize=(10, 6))\n",
    "# plt.barh(nausea[\"arm_display\"], nausea[\"percent_with_event\"])\n",
    "# plt.xlabel(\"Nausea (% participants with ≥1 event)\")\n",
    "# plt.ylabel(\"Drug / dose\")\n",
    "# plt.title(\"Nausea incidence by clinically relevant arm\")\n",
    "# plt.tight_layout()\n",
    "# plt.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 200,
   "id": "7c40b575",
   "metadata": {},
   "outputs": [],
   "source": [
    "df_trials.to_csv(\"trials.csv\", index=False)\n",
    "new_df_ae.to_csv(\"ae.csv\", index=False)\n",
    "df_baseline.to_csv(\"baseline.csv\", index=False)\n",
    "df_arms.to_csv(\"arms.csv\", index=False)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "764daaa3",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Found 9 unique indication strings\n"
     ]
    }
   ],
   "source": [
    "indications = (\n",
    "    df_trials[\"indication\"]\n",
    "    .dropna()\n",
    "    .astype(str)\n",
    "    .drop_duplicates()\n",
    "    .sort_values()\n",
    "    .tolist()\n",
    ")\n",
    "print(f\"Found {len(indications)} unique indication strings\")\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "id": "ab3e9064",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>indication_raw</th>\n",
       "      <th>indication_group</th>\n",
       "      <th>notes</th>\n",
       "      <th>confidence</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Non-alcoholic fatty liver disease (NAFLD)</td>\n",
       "      <td>NAFLD/NASH</td>\n",
       "      <td>Grouped NAFLD with NASH for cross-trial analysis</td>\n",
       "      <td>high</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Obesity</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>NaN</td>\n",
       "      <td>high</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Overweight or Obesity</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>Collapsed overweight into obesity</td>\n",
       "      <td>high</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Overweight or obesity</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>Collapsed overweight into obesity</td>\n",
       "      <td>high</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Type 2 Diabetes</td>\n",
       "      <td>Type 2 diabetes</td>\n",
       "      <td>NaN</td>\n",
       "      <td>high</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                              indication_raw indication_group  \\\n",
       "0  Non-alcoholic fatty liver disease (NAFLD)       NAFLD/NASH   \n",
       "1                                    Obesity          Obesity   \n",
       "2                      Overweight or Obesity          Obesity   \n",
       "3                      Overweight or obesity          Obesity   \n",
       "4                            Type 2 Diabetes  Type 2 diabetes   \n",
       "\n",
       "                                              notes confidence  \n",
       "0  Grouped NAFLD with NASH for cross-trial analysis       high  \n",
       "1                                               NaN       high  \n",
       "2                 Collapsed overweight into obesity       high  \n",
       "3                 Collapsed overweight into obesity       high  \n",
       "4                                               NaN       high  "
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "def build_indication_prompt(labels):\n",
    "    \"\"\"\n",
    "    labels: list of raw indication strings\n",
    "    \"\"\"\n",
    "    instructions = \"\"\"\n",
    "You are harmonizing clinical trial indication labels.\n",
    "\n",
    "Goal:\n",
    "- Map raw indication strings from trial publications into a single, normalized\n",
    "  indication_group that can be used for cross-trial analysis.\n",
    "\n",
    "Rules:\n",
    "- If two raw labels describe essentially the same patient population, they\n",
    "  should share the SAME indication_group string.\n",
    "- Keep important distinctions that change the biology or safety context, but collapse distinctions that a reasonable biotech analyst wouldn't care about (obesity vs overweight are the same thing and would all be obesity):\n",
    "\n",
    "  e.g., \"Type 2 diabetes\" vs \"Obesity without diabetes\" vs\n",
    "  \"Obesity with type 2 diabetes\".\n",
    "- Normalize wording and spelling but keep groups intuitive and human-readable:\n",
    "  e.g. \"Type 2 diabetes\", \"Obesity\", \"Obesity + T2D\", \"NAFLD/NASH\".\n",
    "- If a label is very vague (e.g. \"Overweight or obese with comorbidities\"),\n",
    "  choose a concise but reasonable indication_group such as\n",
    "  \"Obesity with cardiometabolic risk\".\n",
    "\n",
    "For EACH label I give you, output a JSON object with:\n",
    "- \"indication_raw\": the original label string.\n",
    "- \"indication_group\": a concise, normalized indication group as defined above.\n",
    "- \"notes\": (optional) short explanation if needed.\n",
    "- \"confidence\": \"high\", \"medium\", or \"low\".\n",
    "\n",
    "Return ONLY a JSON list (array) of these objects, with one object per input label,\n",
    "and no extra commentary.\n",
    "\n",
    "Here are the raw indication labels:\n",
    "\"\"\"\n",
    "    body = \"\\n\".join(f\"- {lab}\" for lab in labels)\n",
    "    return instructions + \"\\n\" + body\n",
    "\n",
    "\n",
    "prompt = build_indication_prompt(indications)\n",
    "\n",
    "# Use the same client you used for AE mapping; adjust if your call pattern differs\n",
    "indication_response = client.chat.completions.create(\n",
    "    model=\"gpt-5\",\n",
    "    messages=[{\"role\": \"user\", \"content\": prompt}],\n",
    "    response_format={\"type\": \"json_object\"},\n",
    ")\n",
    "\n",
    "indication_text = indication_response.choices[0].message.content\n",
    "result = json.loads(indication_text)\n",
    "\n",
    "# handle possible response wrappers (check for common keys)\n",
    "if isinstance(result, dict):\n",
    "    if \"results\" in result:\n",
    "        result = result[\"results\"]\n",
    "    elif \"result\" in result:\n",
    "        result = result[\"result\"]\n",
    "    # If result is still a dict but not a list, it might be the array itself\n",
    "    # Check if it looks like it should be a list\n",
    "    if not isinstance(result, list):\n",
    "        # Try to find a list value in the dict\n",
    "        for key, value in result.items():\n",
    "            if isinstance(value, list):\n",
    "                result = value\n",
    "                break\n",
    "\n",
    "# Ensure result is a list before creating DataFrame\n",
    "if not isinstance(result, list):\n",
    "    raise ValueError(f\"Expected a list but got {type(result)}: {result}\")\n",
    "\n",
    "indication_mapping = pd.DataFrame(result)\n",
    "indication_mapping.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "c1b4c7e9",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Verify that indication_mapping has the required columns\n",
    "required_cols = [\"indication_raw\", \"indication_group\"]\n",
    "missing_cols = [col for col in required_cols if col not in indication_mapping.columns]\n",
    "if missing_cols:\n",
    "    print(f\"Warning: indication_mapping is missing columns: {missing_cols}\")\n",
    "    print(f\"Available columns: {list(indication_mapping.columns)}\")\n",
    "    raise KeyError(f\"Missing required columns: {missing_cols}\")\n",
    "\n",
    "df_trials = df_trials.merge(\n",
    "    indication_mapping[[\"indication_raw\", \"indication_group\"]],\n",
    "    left_on=\"indication\",\n",
    "    right_on=\"indication_raw\",\n",
    "    how=\"left\",\n",
    ")\n",
    "\n",
    "df_trials.drop(columns=[\"indication_raw\"], inplace=True)\n",
    "\n",
    "# Optional: inspect and/or save\n",
    "df_trials[[\"trial_id\", \"indication\", \"indication_group\"]].drop_duplicates().head()\n",
    "\n",
    "# Optional save\n",
    "df_trials.to_csv(\"trials_with_indication_groups.csv\", index=False)\n",
    "indication_mapping.to_csv(\"indication_mapping.csv\", index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "id": "ff3596cc",
   "metadata": {},
   "outputs": [],
   "source": [
    "### adding in metadata to trials with a dictionary with drug name and half life \n",
    "drug_half_life = {\n",
    "    \"Semaglutide\": 7,\n",
    "    \"Exenatide\": .1,\n",
    "    \"Liraglutide\": 0.5,\n",
    "    \"Dulaglutide\": 4.85,\n",
    "    \"albiglutide\": 7,\n",
    "    \"Retatrutide\": 6,\n",
    "    \"Tirzepatide\": 5,\n",
    "    \"Lixisenatide\": 0.125,\n",
    "    \"Exenatide (Exendin-4)\": .1,\n",
    "    \"Albiglutide\":7,\n",
    "    \"Exenatide (Byetta)\": .1,\n",
    "}\n",
    "trials_with_drug_half_life = df_trials.copy()\n",
    "trials_with_drug_half_life[\"drug_half_life\"] = trials_with_drug_half_life[\"drug_name\"].map(drug_half_life)\n",
    "trials_with_drug_half_life.to_csv(\"trials_with_indication_groups.csv\", index=False)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "id": "f465b7bc",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>trial_id</th>\n",
       "      <th>citation</th>\n",
       "      <th>drug_name</th>\n",
       "      <th>phase</th>\n",
       "      <th>indication</th>\n",
       "      <th>trial_duration</th>\n",
       "      <th>trial_duration_weeks</th>\n",
       "      <th>safety_population_definition</th>\n",
       "      <th>nct_number</th>\n",
       "      <th>sponsor</th>\n",
       "      <th>indication_group</th>\n",
       "      <th>drug_half_life</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>NCT01272219</td>\n",
       "      <td>N Engl J Med 2015;373:11-22. DOI: 10.1056/NEJM...</td>\n",
       "      <td>Liraglutide</td>\n",
       "      <td>Not specified</td>\n",
       "      <td>Weight management in overweight or obese adult...</td>\n",
       "      <td>56 weeks</td>\n",
       "      <td>56.0</td>\n",
       "      <td>All randomized participants who received at le...</td>\n",
       "      <td>NCT01272219</td>\n",
       "      <td>Novo Nordisk</td>\n",
       "      <td>Obesity without diabetes</td>\n",
       "      <td>0.500</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>NCT03495102</td>\n",
       "      <td>Diabetes Care 2021;44:765–773 | https://doi.or...</td>\n",
       "      <td>Dulaglutide</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Type 2 Diabetes</td>\n",
       "      <td>52 weeks</td>\n",
       "      <td>52.0</td>\n",
       "      <td>All randomly assigned patients who received at...</td>\n",
       "      <td>NCT03495102</td>\n",
       "      <td>Eli Lilly and Company</td>\n",
       "      <td>Type 2 diabetes</td>\n",
       "      <td>4.850</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>NCT03548935</td>\n",
       "      <td>N Engl J Med 2021;384:989-1002. DOI: 10.1056/N...</td>\n",
       "      <td>Semaglutide</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Overweight or Obesity</td>\n",
       "      <td>68 weeks</td>\n",
       "      <td>68.0</td>\n",
       "      <td>All randomized participants exposed to at leas...</td>\n",
       "      <td>NCT03548935</td>\n",
       "      <td>Novo Nordisk</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>7.000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>NCT00849017</td>\n",
       "      <td>Diabetologia (2016) 59:266-274 DOI 10.1007/s00...</td>\n",
       "      <td>albiglutide</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Type 2 Diabetes Mellitus</td>\n",
       "      <td>52 weeks</td>\n",
       "      <td>52.0</td>\n",
       "      <td>All randomized participants who received at le...</td>\n",
       "      <td>NCT00849017</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>Type 2 diabetes</td>\n",
       "      <td>7.000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>NCT05567796</td>\n",
       "      <td>N Engl J Med 2025;393:635-47. DOI: 10.1056/NEJ...</td>\n",
       "      <td>Cagrilintide-Semaglutide</td>\n",
       "      <td>3a</td>\n",
       "      <td>Overweight or Obesity</td>\n",
       "      <td>68-week</td>\n",
       "      <td>68.0</td>\n",
       "      <td>all the participants who underwent randomizati...</td>\n",
       "      <td>NCT05567796</td>\n",
       "      <td>Novo Nordisk</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>NCT04707469</td>\n",
       "      <td>Vanita R Aroda, Jens Aberle, Lars Bardtrum, Er...</td>\n",
       "      <td>oral semaglutide</td>\n",
       "      <td>3b</td>\n",
       "      <td>type 2 diabetes</td>\n",
       "      <td>68 weeks</td>\n",
       "      <td>68.0</td>\n",
       "      <td>all participants who received at least one dos...</td>\n",
       "      <td>NCT04707469</td>\n",
       "      <td>Novo Nordisk</td>\n",
       "      <td>Type 2 diabetes</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Exenatide (Exendin-4)_7</td>\n",
       "      <td>Diabetes Care 28:1092-1100, 2005</td>\n",
       "      <td>Exenatide (Exendin-4)</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Type 2 Diabetes</td>\n",
       "      <td>30 weeks</td>\n",
       "      <td>30.0</td>\n",
       "      <td>All randomized participants who received at le...</td>\n",
       "      <td>N/A</td>\n",
       "      <td>Amylin Pharmaceuticals, Eli Lilly</td>\n",
       "      <td>Type 2 diabetes</td>\n",
       "      <td>0.100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>NCT04944992</td>\n",
       "      <td>Journal of Hepatology, October 2023, vol. 79, ...</td>\n",
       "      <td>Efinopegdutide</td>\n",
       "      <td>IIa</td>\n",
       "      <td>Non-alcoholic fatty liver disease (NAFLD)</td>\n",
       "      <td>24 weeks</td>\n",
       "      <td>24.0</td>\n",
       "      <td>All randomized participants who received at le...</td>\n",
       "      <td>NCT04944992</td>\n",
       "      <td>Merck Sharp &amp; Dohme LLC, a subsidiary of Merck...</td>\n",
       "      <td>NAFLD/NASH</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>NCT00688701</td>\n",
       "      <td>Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G,...</td>\n",
       "      <td>Lixisenatide</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Type 2 Diabetes</td>\n",
       "      <td>12-week</td>\n",
       "      <td>12.0</td>\n",
       "      <td>All randomized patients exposed to at least on...</td>\n",
       "      <td>NCT00688701</td>\n",
       "      <td>Sanofi-aventis</td>\n",
       "      <td>Type 2 diabetes</td>\n",
       "      <td>0.125</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>NCT00308139</td>\n",
       "      <td>Buse JB, Drucker DJ, Taylor KL, et al. DURATIO...</td>\n",
       "      <td>Exenatide</td>\n",
       "      <td>Not specified</td>\n",
       "      <td>Type 2 Diabetes</td>\n",
       "      <td>52 weeks</td>\n",
       "      <td>52.0</td>\n",
       "      <td>All randomized participants who received at le...</td>\n",
       "      <td>NCT00308139</td>\n",
       "      <td>Amylin Pharmaceuticals and Eli Lilly &amp; Company</td>\n",
       "      <td>Type 2 diabetes</td>\n",
       "      <td>0.100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>NCT05669599</td>\n",
       "      <td>N Engl J Med 2025;393:843-57. DOI: 10.1056/NEJ...</td>\n",
       "      <td>Maridebart Cafraglutide</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>52 weeks</td>\n",
       "      <td>52.0</td>\n",
       "      <td>All randomized participants who received at le...</td>\n",
       "      <td>NCT05669599</td>\n",
       "      <td>Amgen</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>NCT00381342</td>\n",
       "      <td>Clinical Therapeutics/Volume 30, Number 8, 2008</td>\n",
       "      <td>Exenatide</td>\n",
       "      <td>Not specified</td>\n",
       "      <td>Type 2 Diabetes</td>\n",
       "      <td>24 weeks</td>\n",
       "      <td>24.0</td>\n",
       "      <td>All randomized patients who received ≥1 dose o...</td>\n",
       "      <td>NCT00381342</td>\n",
       "      <td>Amylin Pharmaceuticals, Inc. and Eli Lilly and...</td>\n",
       "      <td>Type 2 diabetes</td>\n",
       "      <td>0.100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>NCT02465515</td>\n",
       "      <td>Lancet 2018; 392: 1519–29</td>\n",
       "      <td>Albiglutide</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Type 2 Diabetes and Cardiovascular Disease</td>\n",
       "      <td>1.6 years</td>\n",
       "      <td>83.2</td>\n",
       "      <td>All randomized participants who received at le...</td>\n",
       "      <td>NCT02465515</td>\n",
       "      <td>GlaxoSmithKline</td>\n",
       "      <td>Type 2 diabetes with cardiovascular disease</td>\n",
       "      <td>7.000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>NCT04184622</td>\n",
       "      <td>N Engl J Med 2022;387:205-16. DOI: 10.1056/NEJ...</td>\n",
       "      <td>Tirzepatide</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>72 weeks</td>\n",
       "      <td>72.0</td>\n",
       "      <td>Adults with a BMI of 30 or more, or 27 or more...</td>\n",
       "      <td>NCT04184622</td>\n",
       "      <td>Eli Lilly</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>5.000</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>Exenatide (Byetta)_15</td>\n",
       "      <td>Proc (Bayl Univ Med Cent) 2006;19:281-284</td>\n",
       "      <td>Exenatide (Byetta)</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Type 2 Diabetes Mellitus</td>\n",
       "      <td>30 weeks</td>\n",
       "      <td>30.0</td>\n",
       "      <td>All patients who received one dose of medication</td>\n",
       "      <td>N/A</td>\n",
       "      <td>Amylin Pharmaceuticals, Inc.</td>\n",
       "      <td>Type 2 diabetes</td>\n",
       "      <td>0.100</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>NCT00707031</td>\n",
       "      <td>Rosenstock J, Raccah D, Koranyi L, Maffei L, B...</td>\n",
       "      <td>Lixisenatide</td>\n",
       "      <td>Phase III</td>\n",
       "      <td>Type 2 Diabetes</td>\n",
       "      <td>24-week</td>\n",
       "      <td>24.0</td>\n",
       "      <td>All randomized participants exposed to at leas...</td>\n",
       "      <td>NCT00707031</td>\n",
       "      <td>Sanofi</td>\n",
       "      <td>Type 2 diabetes</td>\n",
       "      <td>0.125</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>NCT05035095</td>\n",
       "      <td>Lancet 2023; 402: 705–19</td>\n",
       "      <td>Oral semaglutide</td>\n",
       "      <td>Phase 3</td>\n",
       "      <td>Overweight or obesity</td>\n",
       "      <td>68 weeks</td>\n",
       "      <td>68.0</td>\n",
       "      <td>Participants who received at least one dose of...</td>\n",
       "      <td>NCT05035095</td>\n",
       "      <td>Novo Nordisk</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>NaN</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>NCT04881760</td>\n",
       "      <td>N Engl J Med 2023;389:514-26. DOI: 10.1056/NEJ...</td>\n",
       "      <td>Retatrutide</td>\n",
       "      <td>Phase 2</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>48 weeks</td>\n",
       "      <td>48.0</td>\n",
       "      <td>All randomized participants who took at least ...</td>\n",
       "      <td>NCT04881760</td>\n",
       "      <td>Eli Lilly</td>\n",
       "      <td>Obesity</td>\n",
       "      <td>6.000</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                   trial_id  \\\n",
       "0               NCT01272219   \n",
       "1               NCT03495102   \n",
       "2               NCT03548935   \n",
       "3               NCT00849017   \n",
       "4               NCT05567796   \n",
       "5               NCT04707469   \n",
       "6   Exenatide (Exendin-4)_7   \n",
       "7               NCT04944992   \n",
       "8               NCT00688701   \n",
       "9               NCT00308139   \n",
       "10              NCT05669599   \n",
       "11              NCT00381342   \n",
       "12              NCT02465515   \n",
       "13              NCT04184622   \n",
       "14    Exenatide (Byetta)_15   \n",
       "15              NCT00707031   \n",
       "16              NCT05035095   \n",
       "17              NCT04881760   \n",
       "\n",
       "                                             citation  \\\n",
       "0   N Engl J Med 2015;373:11-22. DOI: 10.1056/NEJM...   \n",
       "1   Diabetes Care 2021;44:765–773 | https://doi.or...   \n",
       "2   N Engl J Med 2021;384:989-1002. DOI: 10.1056/N...   \n",
       "3   Diabetologia (2016) 59:266-274 DOI 10.1007/s00...   \n",
       "4   N Engl J Med 2025;393:635-47. DOI: 10.1056/NEJ...   \n",
       "5   Vanita R Aroda, Jens Aberle, Lars Bardtrum, Er...   \n",
       "6                    Diabetes Care 28:1092-1100, 2005   \n",
       "7   Journal of Hepatology, October 2023, vol. 79, ...   \n",
       "8   Fonseca VA, Alvarado-Ruiz R, Raccah D, Boka G,...   \n",
       "9   Buse JB, Drucker DJ, Taylor KL, et al. DURATIO...   \n",
       "10  N Engl J Med 2025;393:843-57. DOI: 10.1056/NEJ...   \n",
       "11    Clinical Therapeutics/Volume 30, Number 8, 2008   \n",
       "12                          Lancet 2018; 392: 1519–29   \n",
       "13  N Engl J Med 2022;387:205-16. DOI: 10.1056/NEJ...   \n",
       "14          Proc (Bayl Univ Med Cent) 2006;19:281-284   \n",
       "15  Rosenstock J, Raccah D, Koranyi L, Maffei L, B...   \n",
       "16                           Lancet 2023; 402: 705–19   \n",
       "17  N Engl J Med 2023;389:514-26. DOI: 10.1056/NEJ...   \n",
       "\n",
       "                   drug_name          phase  \\\n",
       "0                Liraglutide  Not specified   \n",
       "1                Dulaglutide        Phase 3   \n",
       "2                Semaglutide        Phase 3   \n",
       "3                albiglutide        Phase 3   \n",
       "4   Cagrilintide-Semaglutide             3a   \n",
       "5           oral semaglutide             3b   \n",
       "6      Exenatide (Exendin-4)      Phase III   \n",
       "7             Efinopegdutide            IIa   \n",
       "8               Lixisenatide      Phase III   \n",
       "9                  Exenatide  Not specified   \n",
       "10   Maridebart Cafraglutide        Phase 2   \n",
       "11                 Exenatide  Not specified   \n",
       "12               Albiglutide        Phase 3   \n",
       "13               Tirzepatide        Phase 3   \n",
       "14        Exenatide (Byetta)      Phase III   \n",
       "15              Lixisenatide      Phase III   \n",
       "16          Oral semaglutide        Phase 3   \n",
       "17               Retatrutide        Phase 2   \n",
       "\n",
       "                                           indication trial_duration  \\\n",
       "0   Weight management in overweight or obese adult...       56 weeks   \n",
       "1                                     Type 2 Diabetes       52 weeks   \n",
       "2                               Overweight or Obesity       68 weeks   \n",
       "3                            Type 2 Diabetes Mellitus       52 weeks   \n",
       "4                               Overweight or Obesity        68-week   \n",
       "5                                     type 2 diabetes       68 weeks   \n",
       "6                                     Type 2 Diabetes       30 weeks   \n",
       "7           Non-alcoholic fatty liver disease (NAFLD)       24 weeks   \n",
       "8                                     Type 2 Diabetes        12-week   \n",
       "9                                     Type 2 Diabetes       52 weeks   \n",
       "10                                            Obesity       52 weeks   \n",
       "11                                    Type 2 Diabetes       24 weeks   \n",
       "12         Type 2 Diabetes and Cardiovascular Disease      1.6 years   \n",
       "13                                            Obesity       72 weeks   \n",
       "14                           Type 2 Diabetes Mellitus       30 weeks   \n",
       "15                                    Type 2 Diabetes        24-week   \n",
       "16                              Overweight or obesity       68 weeks   \n",
       "17                                            Obesity       48 weeks   \n",
       "\n",
       "    trial_duration_weeks                       safety_population_definition  \\\n",
       "0                   56.0  All randomized participants who received at le...   \n",
       "1                   52.0  All randomly assigned patients who received at...   \n",
       "2                   68.0  All randomized participants exposed to at leas...   \n",
       "3                   52.0  All randomized participants who received at le...   \n",
       "4                   68.0  all the participants who underwent randomizati...   \n",
       "5                   68.0  all participants who received at least one dos...   \n",
       "6                   30.0  All randomized participants who received at le...   \n",
       "7                   24.0  All randomized participants who received at le...   \n",
       "8                   12.0  All randomized patients exposed to at least on...   \n",
       "9                   52.0  All randomized participants who received at le...   \n",
       "10                  52.0  All randomized participants who received at le...   \n",
       "11                  24.0  All randomized patients who received ≥1 dose o...   \n",
       "12                  83.2  All randomized participants who received at le...   \n",
       "13                  72.0  Adults with a BMI of 30 or more, or 27 or more...   \n",
       "14                  30.0   All patients who received one dose of medication   \n",
       "15                  24.0  All randomized participants exposed to at leas...   \n",
       "16                  68.0  Participants who received at least one dose of...   \n",
       "17                  48.0  All randomized participants who took at least ...   \n",
       "\n",
       "     nct_number                                            sponsor  \\\n",
       "0   NCT01272219                                       Novo Nordisk   \n",
       "1   NCT03495102                              Eli Lilly and Company   \n",
       "2   NCT03548935                                       Novo Nordisk   \n",
       "3   NCT00849017                                    GlaxoSmithKline   \n",
       "4   NCT05567796                                       Novo Nordisk   \n",
       "5   NCT04707469                                       Novo Nordisk   \n",
       "6           N/A                  Amylin Pharmaceuticals, Eli Lilly   \n",
       "7   NCT04944992  Merck Sharp & Dohme LLC, a subsidiary of Merck...   \n",
       "8   NCT00688701                                     Sanofi-aventis   \n",
       "9   NCT00308139     Amylin Pharmaceuticals and Eli Lilly & Company   \n",
       "10  NCT05669599                                              Amgen   \n",
       "11  NCT00381342  Amylin Pharmaceuticals, Inc. and Eli Lilly and...   \n",
       "12  NCT02465515                                    GlaxoSmithKline   \n",
       "13  NCT04184622                                          Eli Lilly   \n",
       "14          N/A                       Amylin Pharmaceuticals, Inc.   \n",
       "15  NCT00707031                                             Sanofi   \n",
       "16  NCT05035095                                       Novo Nordisk   \n",
       "17  NCT04881760                                          Eli Lilly   \n",
       "\n",
       "                               indication_group  drug_half_life  \n",
       "0                      Obesity without diabetes           0.500  \n",
       "1                               Type 2 diabetes           4.850  \n",
       "2                                       Obesity           7.000  \n",
       "3                               Type 2 diabetes           7.000  \n",
       "4                                       Obesity             NaN  \n",
       "5                               Type 2 diabetes             NaN  \n",
       "6                               Type 2 diabetes           0.100  \n",
       "7                                    NAFLD/NASH             NaN  \n",
       "8                               Type 2 diabetes           0.125  \n",
       "9                               Type 2 diabetes           0.100  \n",
       "10                                      Obesity             NaN  \n",
       "11                              Type 2 diabetes           0.100  \n",
       "12  Type 2 diabetes with cardiovascular disease           7.000  \n",
       "13                                      Obesity           5.000  \n",
       "14                              Type 2 diabetes           0.100  \n",
       "15                              Type 2 diabetes           0.125  \n",
       "16                                      Obesity             NaN  \n",
       "17                                      Obesity           6.000  "
      ]
     },
     "execution_count": 24,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "trials_with_drug_half_life"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "507e1c5e",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
